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Nogo Domains and a Nogo Receptor: Minireview
Implications for Axon Regeneration
tion was extended by impressive studies showing that
retinal neurons can form long projections in peripheral
nerve grafts (David and Aguayo, 1981). These results
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show that failure to regenerate is not purely an intrinsicHarvard Medical School
deficit of CNS neurons, and is blocked by the CNS envi-Boston, Massachusetts 02115
ronment.
Two main sites have been considered for the location
Diagnosis: You should say of him: “One having a crushed of CNS factors that might inhibit axon regeneration (Fig-
vertebra in his neck; he is unconscious of his two arms, ure 1). One site is the scar that forms at the region of
his two legs, he is speechless. An ailment not to be injury. Following CNS injury the central area of necrosis
treated.” is infiltrated by glia and other nonneuronal cells, and a
–Edwin Smith Surgical Papyrus, c. 2500–1600 B.C. fibrous scar forms. Axons do not extend through the
scar and appear to be inhibited by it, with the axon tips
forming club-like structures that can remain in place forUnfortunately, little has changed clinically in the several
months or even years. Molecular components that maythousand years since this anonymous author gave us
contribute to this inhibitory activity include chondroitinthe first known descriptions of the tragic consequences
sulfate proteoglycans (CSPG), tenascin, and semapho-of central nervous system (CNS) injury, and the limited
rin-3A, which are upregulated in the region of scarringtherapeutic options (Breasted, 1930). Today, it is esti-
and are inhibitory to axon growth in culture (Letourneaumated that more than 250,000 Americans have spinal
et al., 1994; Davies et al., 1999; Pasterkamp et al., 1999,cord injuries, with 11,000 new cases every year (Berko-
and references therein). Moreover, glial scar tissuewitz et al., 1998). When axonal connections are damaged
placed in culture can be converted to a permissive sub-in the adult brain or spinal cord, they show an extremely
strate by enzymatic removal of glycosaminoglycans,limited ability to regenerate, even though axons can
supporting the idea that CSPG is an important compo-grow and regenerate efficiently in the embryonic CNS,
nent. It is worth bearing in mind that proteoglycans bindand in the adult peripheral nervous system. What are
many other molecules, and their role could be as a scaf-
the reasons for this selective shutdown of regeneration
fold that presents molecular cues to the responding cell.
in the adult CNS? Factors that may play a role can be
The other main proposal is that inhibitors would be
grouped in two categories: intrinsic properties of CNS
broadly distributed in the myelin that ensheaths axons
neurons that may make them incapable of regenerating,
in white matter tracts of the adult CNS. Supporting this
or extrinsic factors in the environment that may influence idea, the loss of regeneration potential during develop-
axon growth positively or negatively (reviewed by Horner ment correlates roughly with the onset of myelination.
and Gage, 2000). Here, we focus on extrinsic negative Moreover, myelin carpets or oligodendrocytes, the cells
factors, particularly recent studies of the inhibitory mole- that produce CNS myelin, are poor substrates for axon
cule Nogo. After many years of remarkable studies outgrowth in vitro. Important experiments by Schwab
showing effects on axon growth in vitro and even partial and colleagues showed that myelin can be converted
recovery of function in rodent models of spinal cord to a more permissive in vitro axon substrate by addition
injury after treatment with anti-Nogo antibodies (Breg- of the monoclonal antibody IN-1, providing persuasive
man et al., 1995), Nogo was cloned last year by three evidence for inhibitors in myelin (Caroni and Schwab,
groups, in the labs of Martin Schwab, Stephen Strittmat- 1988). IN-1 was raised against a purified 250 kilodalton
ter, and Frank Walsh (Chen et al., 2000; GrandPre et al., protein named NI-250, a neurite inhibitory activity of
2000; Prinjha et al., 2000). A surprising aspect of these CNS myelin, and also recognizes a smaller inhibitory
initial studies is that the different groups identified inhibi- protein, NI-35, found in rat but not bovine or human
tory activity in two entirely different domains of Nogo. myelin. Most excitingly, IN-1 treatment of rats with spinal
A recent study from the Strittmatter group now extends cord injury caused an improvement in regeneration of
the characterization of these two domains and for the corticospinal axons, as well as enhanced recovery of
first time identifies a receptor that can mediate Nogo behavioral function (Bregman et al., 1995).
activity (Fournier et al., 2001). These studies bring a Molecular characterization of the components of my-
promising new molecular focus to the study of CNS elin inhibitory activity has been a major goal. One such
regeneration. component may be myelin associated glycoprotein
Inhibitors of Axon Growth in the CNS (MAG), which is an inhibitor of neurite outgrowth in cul-
The idea that factors in the CNS environment could ture, although there have been varying reports of the
prevent regeneration dates to the early 20th century. effect of MAG gene disruption on regeneration in vivo
Tello showed in 1911, as later described by Cajal (1928), (reviewed by Filbin, 1996). In view of the actions of IN-1
antibody in spinal cord regeneration, molecular cloningthat the inability of adult CNS neurons to extend axonal
of the key molecule or molecules it recognizes was ea-processes could be overcome by giving them the per-
gerly awaited.missive environment of a peripheral nerve. This observa-
Molecular Studies of Nogo: Two Inhibitory Domains
An important advance last year came with the descrip-* To whom correspondence should be addressed (e-mail: flanagan@
hms.harvard.edu). tion of cDNA clones encoding a protein, termed Nogo,
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Figure 2. Structure of Nogo Isoforms and the NgR Receptor
Three Nogo isoforms, Nogo-A, -B, and -C, are generated by alterna-
tive RNA splicing or promoter usage of a single gene. A model for
Figure 1. Damage of CNS Axons and Potential Mechanisms of Re- Nogo membrane topology based on current evidence is illustrated
covery at the top (not to scale), with the region common to all three isoforms
(A) Axons in CNS white matter are wrapped in myelin, produced by containing two transmembrane domains (black; TM 1 and TM 2)
oligodendrocytes. and an extracellular loop between them (red), and the rest of the
(B) Following trauma, a glial scar forms at the injury site, and distal molecule cytoplasmic. However, other membrane topologies may
nerve segments degenerate. CNS axons show very limited capacity be possible. Nogo-66 and amino-Nogo are artificial recombinant
to regenerate. fragments, both of which show in vitro inhibitory activity. NgR is a
(C) Neutralization of inhibitors may allow improvements in function receptor that can mediate inhibition by Nogo-66. NgR contains a
through regeneration of original axon pathways. Alternatively, translocation signal sequence (Signal), eight leucine-rich repeat mo-
sprouting of damaged axons, or other undamaged axon tracts, may tifs (LRR), an LRR carboxy terminal motif (LRRCT), and a GPI lipid
form compensatory new pathways. anchor that tethers it to the membrane.
nized by antibody IN-1. It causes growth cone collapseby three groups (Chen et al., 2000; GrandPre et al., 2000;
Prinjha et al., 2000). All three relied on peptide se- and inhibition of neurite outgrowth from neurons that
are sensitive to CNS myelin, and new antibodies raisedquences derived from the purified bovine homolog of
NI-250 (Spillmann et al., 1998), allowing isolation of against Nogo-A neutralize much of the in vitro inhibitory
activity of CNS myelin. Thus, in vitro gain- and loss-of-clones from cDNA libraries, or identification of nucleic
acid sequences in the Genbank database. function experiments, as well as expression patterns,
all support a role for Nogo as an important componentThe cDNAs identified in these studies encode three
Nogo isoforms, designated Nogo-A, -B, and -C, pre- of CNS myelin inhibitory activity.
Other important features of Nogo were unexpectedsumed to be generated by alternative RNA splicing or
promoter usage of a single gene (Figure 2). Nogo-A and are still not well understood. Two distinct inhibitory
domains have been described. Somewhat confusingly,appears to be NI-250, and, although it has not been
directly tested, the size of Nogo-B suggests it might the initial reports on cloned Nogo focused on actions
of different domains. Inhibitory activity was found in apotentially be NI-35. In addition to unique regions, the
A, B, and C isoforms share a common carboxy-terminal recombinant fragment of Nogo-A amino-terminal to the
first hydrophobic domain (amino-Nogo) (Prinjha et al.,region. No conventional amino-terminal secretion signal
peptide was found in any of the isoforms. However, 2000). Furthermore, much of the in vitro inhibitory activ-
ity of myelin could be blocked by an antibody raisedthe common region does have two long hydrophobic
stretches that are likely to form transmembrane do- against a peptide from the sequence unique to Nogo-A
(Chen et al., 2000). These results implicated the uniquemains. This common region is homologous to a family
of three proteins called reticulons, because of their amino-terminal domain of Nogo-A as an inhibitory re-
gion. But in the other report, the short 66 residue regionprominent localization in the endoplasmic reticulum
(ER). Although Nogo is likewise found prominently in the (Nogo-66) located between the two hydrophobic do-
mains was shown to have inhibitory activity, implicatingER, it is also present on cell surfaces. The functions of
the previously described reticulon proteins are un- an entirely distinct region that is found in all three Nogo
isoforms (GrandPre et al., 2000).known, although it will now be interesting to see if they
have biological roles analogous to Nogo. The latest study from the Strittmatter group directly
compares soluble recombinant amino-Nogo and Nogo-Several properties of Nogo confirm its role as a nerve
outgrowth inhibitor in CNS myelin. It is found in CNS 66 fragments, confirming that both do have independent
inhibitory activity (Fournier et al., 2001). The study alsowhite matter, including the inner and outer leaflets of
myelin, and in cultured oligodendrocytes, and it is recog- begins to address differences between them. Soluble
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amino-Nogo with an epitope tag required antibody clus- to Nogo-66, become responsive upon infection with a
viral vector encoding NgR cDNA. Taken together, thesetering for activity, whereas Nogo-66 tagged with gluta-
thione S-transferase (GST) did not. Although this sug- results provide convincing evidence that NgR is a func-
tional cell surface receptor that can mediate inhibitorygests a possible molecular difference (Fournier et al.,
2001), GST tags can dimerize, so it remains uncertain effects of Nogo-66.
The cDNA sequence for NgR encodes a protein 473whether Nogo-66 can act as a free monomer. In tests
of specificity for cellular targets, in addition to effects amino acids in length, with a conventional amino-termi-
nal translocation signal sequence. This is followed byon neurons, amino-Nogo inhibited fibroblast spreading,
whereas Nogo-66 did not. Since amino-Nogo acts on eight leucine-rich repeat (LRR) motifs, and an LRR car-
boxy-terminal motif (LRRCT); sequence motifs found indiverse cell types and has an unusual amino acid com-
position rich in prolines and negative charge, it might a variety of cell surface and secreted molecules (Figure
2). A likely human ortholog of mouse NgR was found,act by a mechanism independent of a specific receptor,
or alternatively it may have a receptor located on diverse but so far no other closely homologous sequences that
would suggest a family of related receptors. At the Ccell types.
Another question arising from the initial studies is terminus is a signal for addition of a glycosylphosphati-
dylinositol (GPI) lipid, which was confirmed by enzymaticmembrane topology. In oligodendrocytes or transfected
cells, the Nogo-66 region was detected on intact cells, cleavage to anchor NgR in the membrane. By analogy
with other GPI-anchored receptors, it is likely that NgRwhereas the amino- and carboxy-termini were detected
in transfected cells only after permeabilization, sug- associates with a separate transmembrane signal-trans-
ducing polypeptide, but this remains to be addressedgesting a model where only the short Nogo-66 loop is
exposed on the surface (GrandPre et al., 2000). This in future studies.
Is NgR expressed in a pattern consistent with a rolemodel would probably be the simplest to reconcile with
the presence of two transmembrane domains, since co- in inhibition of CNS regeneration? A Northern blot survey
of tissues showed expression predominantly in brain,translational translocation of the growing polypeptide
could be initiated by the first transmembrane domain consistent with the in vitro assays showing selective
action of Nogo-66 on neurons and not fibroblasts. Byand then terminated by the second. If the amino-Nogo
domain were to be translocated to the surface, this in situ RNA hybridization, NgR is expressed in a wide
variety of CNS neurons, including cerebral cortical neu-would presumably require an unconventional mecha-
nism such as a cryptic internal signal sequence. Alterna- rons, hippocampal neurons, cerebellar Purkinje cells,
and pontine neurons. This includes the cerebral cortextively, release of amino-Nogo-A may require lysis of oli-
godendrocytes, which could occur at sites of CNS injury. pyramidal neurons whose regeneration is enhanced by
IN-1 treatment of injured rat spinal cord and the cerebel-Based on the current evidence, the two domains might
have different functions, even intracellular functions, or lar Purkinje neurons whose sprouting is enhanced by
antibodies to Nogo-A. An antibody to NgR detects thethey might act synergistically. Further studies of Nogo
topology, for example by determining which sites are protein on axons in immunolocalization studies of cul-
tured embryonic spinal neurons. And finally, the anti-exposed for glycosylation in the ER lumen, should help
to understand the actions of amino-Nogo and the other body detects NgR prominently in cultures of late embry-
onic (day 13) chick DRG neurons, which are responsiveNogo domains.
A Receptor for Nogo-66 to Nogo, but little or none in DRG or retinal neurons
of earlier embryonic stages, which are not responsive.An important advance in understanding the mechanism
of action, and the cellular targets, of any ligand is the These expression patterns seem to fit well with expecta-
tions for a receptor mediating Nogo inhibition of axonidentification of a cognate receptor. Work on Nogo-66
therefore took a big step forward with the recent identifi- outgrowth. Since NgR is a functional receptor for
Nogo-66, these studies also support the idea that thecation by Strittmatter’s group of a Nogo-66 receptor
(Fournier et al., 2001). Nogo-66 domain is a strong candidate as an inhibitor
of axon growth in the CNS.They set out to identify this receptor by the alkaline
phosphatase (AP) fusion protein approach (Flanagan Outlook: An Ailment to Be Treated?
The identification of Nogo and NgR represent importantand Cheng, 2000). In initial studies, an AP-Nogo-66 fu-
sion protein was demonstrated to give saturable high- advances in understanding axon inhibition by CNS my-
elin and provide a new molecular basis to study regener-affinity binding to neurons, with a dissociation constant
of 3 nM. This fusion protein also acted as a growth cone ation. In vivo gain- and loss-of-function studies, includ-
ing gene targeting, of Nogo isoforms and NgR will becollapse agent, with a half-maximal response at 1 nM,
consistent with the binding affinity. The AP-Nogo-66 critical to unravel their functions. In addition to testing
effects on recovery from injury, it will be fascinating tofusion protein was then used to screen pools of a mouse
brain cDNA expression library transfected into COS investigate the normal function of Nogo, which has been
speculated to prevent excessive neural plasticity in thecells, resulting in identification of a cDNA that conferred
high-affinity binding activity. The encoded protein was adult CNS.
The relative contributions to regenerative failure ofnamed Nogo-66 receptor (NgR; Figure 2).
To assess whether Nogo-66 and NgR interact directly, the glial scar versus myelin inhibitors has been a long-
standing subject of debate (see Figure 1). On the onemyc-tagged NgR was tested for binding to GST-tagged
Nogo-66 in cell extracts, confirming that the two form hand, it is clear that IN-1 antibody can block myelin
inhibitory activities in culture and can promote recoverya protein complex, although the presence of additional
components is not ruled out. Moreover, early embryonic in lesioned animals. Moreover, impressive regeneration
of up to 50% of corticospinal fibers was recently re-chick retinal neurons, which are not normally sensitive
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Fournier, A.E., GrandPre, T., and Strittmatter, S.M. (2001). Natureported by David and colleagues in a novel approach
409, 341–346.involving vaccination of mice with myelin (Huang et al.,
GrandPre, T., Nakamura, F., Vartanian, T., and Strittmatter, S.M.1999). These studies suggest a key role for myelin inhibi-
(2000). Nature 403, 439–444.tors of regeneration. On the other hand, elegant experi-
Horner, P.J., and Gage, F.H. (2000). Nature 407, 963–970.ments by Silver and colleagues have shown that when
Huang, D.W., McKerracher, L., Braun, P.E., and David, S. (1999).adult neurons are carefully microtransplanted without
Neuron 24, 639–647.creating a glial scar, their axons can regenerate long
Letourneau, P.C., Condic, M.L., and Snow, D.M. (1994). J. Neurosci.distances over heavily myelinated adult CNS tracts. Al-
14, 915–928.
though it might be argued that the transplanted axons
Pasterkamp, R.J., Giger, R.J., Ruitenberg, M.J., Holtmaat, A., De
did not come in contact with the inhibitory inner myelin Wit, J., De Winter, F., and Verhaagen, J. (1999). Mol. Cell. Neurosci.
leaflet, they can even grow through areas of Wallerian 13, 143–166.
degeneration and stall only after encountering a gliotic Prinjha, R., Moore, S.E., Vinson, M., Blake, S., Morrow, R., Christie,
barrier. These results suggest that general myelin inhibi- G., Michlovich, D., Simmons, D.L., and Walsh, F.S. (2000). Nature
403, 383–384.tors may not be as potent in preventing regeneration
as previously thought (Davies et al., 1997, 1999, and Ramon y Cajal, S. (1928). Degeneration and Regeneration of the
Nervous System (New York: Hafner).references therein). Although these various studies may
Spillmann, A.A., Bandtlow, C.E., Lottspeich, F., Keller, F., andinitially seem contradictory, one possibility is that rather
Schwab, M.E. (1998). J. Biol. Chem. 273, 19283–19293.than promoting only direct regeneration of damaged
Z’Graggen, W.J., Fouad, K., Raineteau, O., Metz, G.A.S., Schwab,pathways, neutralization of myelin inhibitors may pro-
M.E., and Kartje, G.L. (2000). J. Neurosci. 20, 6561–6569.mote functional recovery by freeing up CNS plasticity
and thus allowing formation of new pathways that can
compensate for the lost ones (Figure 1C; Z’Graggen et
al., 2000). Alternatively, the studies might be reconciled
if some of the same molecules are general myelin inhibi-
tors and also glial scar inhibitors. The new molecular
tools should help answer these questions.
Moving toward therapeutic approaches for CNS injury
is a complex challenge. In addition to the known inhibi-
tory components, molecules initially identified as devel-
opmental guidance factors such as semaphorins, ephrins,
netrins, and slits probably play a role in the adult CNS.
Especially considering the large number of candidate
inhibitors, rather than blocking them extracellularly, it
may ultimately be more effective to modulate intracellu-
lar pathways of axon responsiveness. Successful regen-
eration depends on additional factors such as survival
of injured neurons and establishment of functional con-
nections. On the positive side, even limited functional
improvement may be valuable clinically. While even this
is likely to take years, the new molecular studies give
grounds for cautious hope. We may at last be in an era
when CNS injury will become an ailment to be treated.
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